KuppingerCole Recognizes Regula as One of the Innovation Leaders in Identity Verification
10.6.2025 03:00:00 CEST | Business Wire | Press Release
Regula, a global developer of forensic devices and identity verification (IDV) solutions, has made its inaugural appearance in the KuppingerCole Leadership Compass for Identity Verification 2025. Mentioned in the Innovation Leaders category, the company is recognized for its 100% in-house R&D, forensic-grade technology, global document coverage, and advanced liveness detection capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760424/en/
Regula’s innovative in-house technology powers fast, seamless identity checks—now recognized by KuppingerCole Analysts.
Specializing in IDV and cybersecurity industry analysis, KuppingerCole forecasts that the global IDV market will grow from $18.4 billion in 2025 to $50.07 billion by 2030, driven by increasing identity fraud, compliance requirements, user expectations, and technological advancements.
As identity verification rapidly shifts toward fully remote and automated environments, innovation has become a key differentiator. According to KuppingerCole, innovation leaders in IDV are defined by taking a customer-oriented upgrade approach, delivering customer-requested and forward-thinking features, while ensuring seamless compatibility with existing systems.
Positioning Regula in the Innovation Leaders category, KuppingerCole analysts highlight: “Regula’s products are mature and often used to supplement other identity verification vendors’ offerings. While not as feature complete as other offerings, Regula is a best-of-breed document and biometric verification solution with strong global coverage. With expertise across diverse industries and a global reach, Regula is positioned as a verification provider with in-house expertise for adaptable and scalable solutions.”
In their Leadership Compass, KuppingerCole analysts pay special attention to the fact that IDV vendors have in-house technology development, strong data privacy policies, wide geographical coverage for their ID databases, and automation and machine learning (ML) to facilitate processes and user experience. On these fronts, Regula stands out by:
- Best-of-breed on-premises document and biometric verification solution.
- Comprehensive ID template database made of 15,000+ templates from 252 countries and territories.
- In-house R&D capabilities with significant domain-specific expertise.
- Advanced liveness detection technology supporting enhanced security.
- A mature organization with products often used to supplement other IDV vendor offerings.
At the heart of Regula’s recognition are its flagship software products, which serve clients in finance, government, healthcare, education, aviation, and more. Regula Document Reader SDK provides automated reading and comprehensive verification of all types of identity documents. It reads data in all document zones, verifies security features—including dynamic ones such as holograms—and cross-checks all the data to spot forgery.
For biometric checks, Regula Face SDK enables real-time face matching, image quality assessment, and both passive and active liveness detection—the latter tested and certified under iBeta’s Presentation Attack Detection (PAD) Level 1 and 2. The solution supports 1:1 face matching and 1:n face identification with advanced spoof detection via texture and movement analysis, using both 2D and 3D methods.
Importantly, Regula’s solutions are designed for privacy-first deployments. All biometric templates are managed locally by the customer, with no data processed or stored by Regula. The face-matching algorithms undergo continuous testing and are benchmarked through programs like the NIST Face Recognition Vendor Test (FRVT).
“Being named an Innovation Leader by KuppingerCole is a significant milestone for us. It highlights our decades-long commitment to building all our solutions in-house, from document verification to biometrics, and doing so with the precision and trustworthiness that customers demand. As identity verification principles and standards rapidly evolve, our focus remains the same: delivering technology that’s not only robust but also deeply practical, scalable, and privacy-conscious,” says Ihar Kliashchou, Chief Technology Officer at Regula.
Recently, Regula has:
- Introduced personal data masking across all its solutions.
- Become the first IDV vendor that enables verification of all dynamic security features in IDs in remote scenarios.
- Made its software compatible with most ID readers on the market.
The full copy of the KuppingerCole Leadership Compass for Identity Verification is available on the official website. To learn more about Regula’s technologies, visit the company’s website.
About KuppingerCole
Founded in 2004, KuppingerCole is a global, independent analyst organization headquartered in Europe. We specialize in providing vendor-neutral advice, expertise, thought leadership, and practical relevance in Cybersecurity, Digital Identity & IAM (Identity and Access Management), Cloud Risk and Security, and Artificial Intelligence, as well as technologies enabling Digital Transformation. We assist companies, corporate users, integrators, and software manufacturers to address both tactical and strategic challenges by making better decisions for their business success. Balancing immediate implementation with long-term viability is central to our philosophy.
For further information, please contact clients@kuppingercole.com.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250609760424/en/
Contacts
Kristina – ks@regulaforensics.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom